€1.79
Your prediction
Syros Pharmaceuticals Inc. Stock
Pros and Cons of Syros Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Syros Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Syros Pharmaceuticals Inc. | 2.860% | 2.874% | 18.543% | -41.118% | -72.879% | -95.214% | - |
Carbylan Therapeutics Inc | 1.730% | -7.368% | -24.138% | -3.297% | -19.266% | -39.726% | -17.510% |
Pharma Mar S.A. | 3.350% | 1.560% | 18.846% | 52.179% | 13.632% | -34.449% | 119.759% |
Clinuvel Pharmaceuticals | 1.330% | -2.581% | -7.066% | -4.615% | -11.374% | -65.583% | -44.395% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial review of the financials for Syros Pharmaceuticals, a company in the volatile pharmaceutical industry, certain numbers immediately draw attention and warrant closer scrutiny. With a market capitalization at approximately $54.98 million and an EBITDA of -$132.625 million, the financial figures suggest the company is in a growth phase but is facing significant challenges in terms of profitability.
General Impressions:
Syros Pharmaceuticals operates in a sector known for high research and development costs, with the potential for substantial returns upon successful product development and approval. This context is essential in understanding why a company might reflect negative earnings before interest, taxes, depreciation, and amortization (EBITDA). Moreover, the lack of dividend payments is common in the industry, as companies often reinvest earnings back into research and product development rather than sharing profits with shareholders.
Comments